ARRY 520 trifluoroacetate

Product Description

ARRY 520 trifluoroacetate is a potent kinesin spindle protein (KSP) inhibitor (IC₅₀ = 6 nM); selective for KSP over >250 other receptors and kinases at a concentration of 10 μM. Displays robust antitumor activity in bortezomib-resistant xenografts either alone or in combination with bortezomib. Induces degradation of Mcl-1; exhibits comparable cytotoxic activity to taxol (Cat. No. 1097) in epithelial ovarian cancer cells. Active in vivo.

Solubility

Preparing Stock Solutions for ARRY 520 trifluoroacetate

The following data is based on the product molecular weight 420.48

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.75 mM	3.17 mL	15.85 mL	31.71 mL
3.75 mM	0.63 mL	3.17 mL	6.34 mL
7.5 mM	0.32 mL	1.59 mL	3.17 mL
37.5 mM	0.06 mL	0.32 mL	0.63 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Tunquist Mcl-1 stability determines mitotic cell fate of human multiple myeloma tumor cells treated with the kinesin spindle protein inhibitor ARRY-520. Mol.Cancer.Ther. 2010 PMID: 20571074
• Kim KSP inhibitor ARRY-520 as a substitute for PacT. in type I ovarian cancer cells. J.Transl.Med. 2009 PMID: 19619321
• Woessner ARRY-520, a novel KSP inhibitor with potent activity in hematological and taxane-resistant tumor models. Anticancer Res. 2009 PMID: 20032381